This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke

Not yet recruiting

Phase Results N/A

Trial Description

This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in Sweden) by physicians in several European countries, such as Italy, United Kingdom, Czech Republic, Sweden, Germany, Poland, Spain, Finland, Portugal, Slovakia, Denmark, Estonia, Norway Belgium, Hungary, Slovenia, Croatia, Austria, Lithuania, France, Greece, Netherlands, Ireland, Ukraine and Iceland.
The aim of this study is to explore the current real world use of dabigatran for stroke prevention in NVAF patients in the post-stroke setting. Secondary data from eligible European patients registered in the SITS registry will be considered; countries of origin are not known a priori.



  • Dabigatran (Pradaxa)Drug
    Intervention Desc: Oral anticoagulant (NOAC) thrombin inhibitor
    ARM 1: Kind: Experimental
    Label: Acute ischemic stroke
    Description: Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke

Trial Population



Type Measure Time Frame Safety Issue
Primary timing of dabigatran treatment initiation after a first ever ischaemic stroke (index event) in NVAF patients At Discharge and at 3 months after index event
Secondary Description of baseline characteristics for patients treated with dabigatran according to time of dabigatran initiation At index stroke date or shortly after (baseline)
Secondary Description of self-reported factors important for physician's decision when to initiate dabigatran and which dabigatran dose is used in the post-ischemic stroke setting for secondary prevention of stroke and safety in NVAF At index stroke date or shortly after (baseline)